UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~December~~January 199, ~~2022~~2023

ALLIED HEALTHCARE PRODUCTS, INC. (Exact name of ~~Company~~registrant as specified in its charter)

Delaware	0-19266	25-1370721
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1720 Sublette Avenue, St. Louis, Missouri
(Address of principal executive offices)

63110
(Zip Code)

~~Company~~Registrant’s telephone number, including area code (314) 771-2400 Not applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the ~~Company~~registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the ~~Company~~registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the ~~Company~~registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $.01	AHPI	The NASDAQ Stock Market, LLC

~~Item~~ITEM 28.0501. ~~Costs~~Other ~~Associated with Exit or Disposal Activities~~Events.

~~Item~~As 2previously reported, on November 10, 2022, Allied Healthcare Products, Inc.06 ~~Material~~(the ~~Impairments~~“Company”) convened its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At that time, there were not present or represented by proxy a sufficient number of shares of the Company’s common stock in order to constitute the required quorum. As a result, the Company adjourned the Annual Meeting until December 9, 2022 at 9:00 a.m. Central Time. At that time, there were again not present or represented by proxy a sufficient number of shares of the Company’s common stock in order to constitute the required quorum. As a result, the Company again adjourned the Annual Meeting until January 9, 2023 at 9:00 a.m. Central Time. As of such time, the Company still has not received proxies representing a sufficient number of shares of the Company’s common stock to constitute a quorum. As a result, the Company again adjourned the Annual Meeting until February 9, 2023 at 9:00 a.m. Central Time.

On December 19, 2022, the Board of Directors of Allied Healthcare Products, Inc. (the “Company”) approved a reduction in force that will impact employees of its St. Louis, Missouri manufacturing facilities and certain employees of its administrative offices. Affected employees have been provided pre-termination notices as required by the federal Worker Adjustment and Retraining Notification (“WARN”) Act and applicable state laws. The reduction in force has been adopted in response to the Company’s ongoing losses from operations.SIGNATURE

~~Workers~~Pursuant ~~will~~to ~~remain employed through~~ the ~~60-day~~requirements ~~WARN~~of ~~Act notice period, at which point~~ the ~~terminations~~Securities ~~will~~Exchange beAct ~~effective. The Company does not expect to incur material severance obligations. The reduction in force will result in the termination~~ of ~~substantially~~1934, ~~all of~~ the ~~Company’s~~registrant ~~union~~has ~~employees,~~duly ~~which~~caused isthis ~~expected~~report to ~~trigger~~ ~~withdrawal~~be ~~liabilities~~signed ~~owed~~on toits ~~certain~~behalf ~~multiemployer pension plans which were recently estimated~~ by ~~such~~the ~~pension~~undersigned ~~plans to be $17.5~~thereunto ~~million.~~duly ~~The actual multiemployer plan withdrawal liability is not likely to be known until the conclusion of any and all appeal processes~~authorized.

The Company expects that it will incur material additional costs in association with actions that are contemplated pursuant to the reduction in force, which could include the impairment of assets and professional fees. The Company is unable at this time to estimate the full amount of such charges and impairments. The Company will file an amendment to this Form 8-K within four business days after it determines an estimate or range of estimates of these costs.

	ALLIED HEALTHCARE PRODUCTS, INC.

	By:
Date: January 11, 2023		/s/ Daniel C. Dunn
		Daniel C. Dunn
		Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALLIED HEALTHCARE PRODUCTS, INC.
	By:
Date: December 22, 2022		/s/ Daniel C. Dunn
		Daniel C. Dunn
		Chief Financial Officer

Filing Compare · ALLIED HEALTHCARE PRODUCTS INC